Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) Director Robert Williamson III bought 18,609 shares of the business's stock in a transaction dated Thursday, November 12th. The shares were bought at an average cost of $0.84 per share, for a total transaction of $15,631.56. Following the completion of the transaction, the director directly owned 28,473 shares of the company's stock, valued at $23,917.32. This trade represents a 188.66% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.
Perspective Therapeutics Stock Performance
NYSEAMERICAN:CATX opened at $0.94 on Monday. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01. Perspective Therapeutics, Inc. has a 1-year low of $0.78 and a 1-year high of $6.16. The stock has a fifty day simple moving average of $2.11 and a 200 day simple moving average of $3.44.
Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). The company had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.06 million. Perspective Therapeutics had a negative return on equity of 42.25% and a negative net margin of 55,866.82%. Equities analysts predict that Perspective Therapeutics, Inc. will post -1.01 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Perspective Therapeutics
A number of institutional investors have recently bought and sold shares of CATX. Commodore Capital LP purchased a new stake in shares of Perspective Therapeutics in the first quarter worth approximately $26,424,000. Avidity Partners Management LP grew its position in Perspective Therapeutics by 88.4% during the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company's stock valued at $25,228,000 after purchasing an additional 2,839,266 shares in the last quarter. Affinity Asset Advisors LLC grew its position in Perspective Therapeutics by 954.9% during the first quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company's stock valued at $13,196,000 after purchasing an additional 2,864,582 shares in the last quarter. Spruce Street Capital LP acquired a new position in Perspective Therapeutics in the 1st quarter valued at approximately $10,955,000. Finally, Nantahala Capital Management LLC increased its stake in Perspective Therapeutics by 7.2% in the 3rd quarter. Nantahala Capital Management LLC now owns 2,492,642 shares of the company's stock valued at $6,855,000 after buying an additional 167,192 shares during the period. 54.66% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research analysts have commented on CATX shares. BTIG Research reiterated a "buy" rating on shares of Perspective Therapeutics in a report on Monday, October 26th. Wedbush restated an "outperform" rating and issued a $7.00 price target (down from $9.00) on shares of Perspective Therapeutics in a research report on Tuesday, November 10th. Royal Bank Of Canada downgraded shares of Perspective Therapeutics from an "outperform" rating to a "sector perform" rating and reduced their price target for the company from $14.00 to $4.00 in a research report on Monday, October 26th. Bank of America decreased their price objective on shares of Perspective Therapeutics from $6.00 to $5.00 and set a "neutral" rating for the company in a research note on Friday, August 14th. Finally, BMO Capital Markets reissued an "outperform" rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Perspective Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $10.10.
View Our Latest Stock Analysis on Perspective Therapeutics
Perspective Therapeutics Company Profile
(
Get Free Report)
Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company's investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Perspective Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perspective Therapeutics wasn't on the list.
While Perspective Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.